Fortrea (FTRE) PT Lowered to $30 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Fortrea (FTRE) PT Lowered to $22 at Evercore ISI
August 12, 2024 1:47 PM EDTEvercore ISI analyst Elizabeth Anderson lowered the price target on Fortrea (NASDAQ: FTRE) to $22.00 (from $27.00) while maintaining a In Line rating.
The analyst comments "If you thought we were done with Olympic themed titles just because the closing ceremony was this weekend,... More
FTRE (FTRE) Misses Q2 EPS by 27c ; Offers Guidance
August 12, 2024 7:04 AM EDTFTRE (NASDAQ: FTRE) reported Q2 EPS of ($0.03), $0.27 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $662.4 million versus the consensus estimate of $797.5 million.
GUIDANCE:
FTRE sees FY2024 revenue of $2.7-2.75 billion, versus the consensus of $2.8... More
Evercore ISI Downgrades Fortrea (FTRE) to In Line
August 8, 2024 5:44 AM EDTEvercore ISI analyst Elizabeth Anderson downgraded Fortrea (NASDAQ: FTRE) from Outperform to In Line with a price target of $27.00 (from $31.00).
The analyst comments "We are moving to the sidelines on FTRE this morning as weaker biotech funding data and pharma R&D spend along with weakening forward indicators for peers who have already reported point to a... More
